STOCK TITAN

Alimera Sciences to Report Fourth Quarter and Full Year 2020 Financial Results on Wednesday, February 24, 2021 and Provide Corporate Update

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings
Rhea-AI Summary

Alimera Sciences, Inc. is set to report its fourth quarter and full year 2020 financial results on February 24, 2021, after the market closes. A conference call will take place on February 25, 2021, at 9:00 AM ET, to discuss the financial results and corporate developments. Participants can pre-register for the call or join via dial-in options. A replay will be available for those unable to attend the live session. Alimera focuses on prescription ophthalmic pharmaceuticals for retinal diseases, addressing significant unmet medical needs.

Positive
  • Upcoming financial results reporting may provide insights into business performance.
  • Conference call aims to engage investors and stakeholders.
Negative
  • None.

Conference Call to be held Thursday, February 25, 2021 at 9:00am Eastern Time

ATLANTA, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals for the treatment of retinal diseases, announces today that it will report fourth quarter and full year 2020 financial results on Wednesday, February 24, 2021 after the market close.

Management will host a conference call at 9:00 AM ET on Thursday, February 25, 2021 to review financial results and provide an update on corporate developments. Following management’s formal remarks, there will be a question and answer session.

Participants are asked to pre-register for the call.

Please note that registered participants will receive their dial-in number upon registration and will dial directly into the call without delay. Those without Internet access or who are unable to pre-register may dial in by calling 1-866-777-2509 (domestic) or 1-412-317-5413 (international). All callers should dial in approximately 10 minutes prior to the scheduled start time and ask to be joined into the Alimera Sciences call. 

The conference call will also be available through a live webcast, which is also available through the company’s website.

A webcast replay of the call will be available approximately one hour after the end of the call through May 25, 2021. The webcast replay can be accessed through the above links or by calling 1-877-344-7529 (domestic) or 1-412-317-0088 (international) and using access code 10152084. The telephonic replay will be available until March 11, 2021.

About Alimera Sciences, Inc.

Alimera Sciences is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals. Alimera is presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and affect millions of people in our aging populations. For more information, please visit www.alimerasciences.com.

For press inquiries:For investor inquiries:
Jules AbrahamScott Gordon
for Alimera Sciencesfor Alimera Sciences
917-885-7378scottg@coreir.com
julesa@coreir.com 

FAQ

What date will Alimera Sciences report its 2020 financial results?

Alimera Sciences will report its 2020 financial results on February 24, 2021.

When is the conference call to discuss Alimera's financial results?

The conference call will be held on February 25, 2021, at 9:00 AM ET.

How can I participate in the Alimera Sciences conference call?

Participants can pre-register for the call or call in at 1-866-777-2509 for domestic and 1-412-317-5413 for international access.

Is a webcast available for the Alimera Sciences conference call?

Yes, a live webcast will also be available for the conference call.

Will there be a replay of the Alimera Sciences conference call?

A replay of the conference call will be available approximately one hour after the call ends.

Alimera Sciences, Inc.

NASDAQ:ALIM

ALIM Rankings

ALIM Latest News

ALIM Stock Data

301.29M
51.48M
5.35%
86.54%
1.06%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States of America
ALPHARETTA